Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Maltose BP EP USP Pharma Grade stands as a refined disaccharide, produced through a controlled enzymatic process from starch, commonly found in corn or wheat sources. The compound appears as a white, crystalline solid with a typical structure of two glucose units bound by a glycosidic linkage. Used extensively within pharmaceutical and food industries, this variant of maltose answers stringent requirements set by pharmacopoeias including British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP). Meeting these standards signifies guaranteed purity, limited presence of impurities, and a consistently replicable profile in each batch manufactured for critical applications.
At the molecular level, maltose holds the formula C12H22O11, with a molar mass around 342.30 g/mol. Each molecule features two alpha-D-glucose units linked via an α(1→4) bond. This direct arrangement influences both the physical shape and chemical behavior. The crystalline form under microscopic examination shows distinctive monoclinic crystals, a property that assists technicians in visual identification and purity checks. Maltose readily dissolves in water, creating clear solutions used in compounding and analytical processes. Its density in the solid state hovers around 1.54-1.58 g/cm3, though factors such as ambient humidity or powder compression can slightly affect the observed value.
Maltose BP EP USP Pharma Grade appears in various forms, each responding to practical needs across industries. Powdered maltose flows easily and integrates into solutions without persistent clumping, offering efficient dosing in laboratory or manufacturing environments. Flakes or crystal clusters find traction for certain processes demanding a consistent melt or slow dissolution. Pearls are less common, but exist in niche markets requiring lower surface area to volume ratios. Maltose in liquid or syrup solutions features in certain pharmaceutical suspensions and diagnostic kit preparations where instant dissolution or stability holds priority. Regardless of form, the solid substance remains stable under cool, dry storage and resists degradation so long as the environment avoids high moisture and extreme temperatures.
Chemically, maltose acts as a reducing sugar: its structure allows the reduction of Benedict’s or Fehling’s solution, a trait that assists analysts in identification and activity assessment. Under normal handling, the product does not exhibit hazardous behavior, as toxicity tests confirm its safe use even in sensitive applications. Inhalation of fine powder calls for basic precautions such as use of dust masks or local extraction, more to prevent discomfort than to mitigate real health risks. Contact with water or gentle heating does not produce harmful byproducts, and the compound remains inert with most pharmaceutical excipients and flavoring agents. Standard safety data sheets list maltose with low environmental impact, supporting its reputation for dependable, minimal-risk use as a chemical and a pharmaceutical ingredient.
Every batch of pharmaceutical-grade maltose starts with food-grade starch, typically obtained from strictly monitored agricultural sources. The conversion processes employ safe, specific enzymes, and each intermediary substance must match quality test points to meet finished product prerequisites. Constant evaluation of purity, absence of heavy metals, and microbial contaminants shape the manufacturing framework. All procedures culminate in products that meet BP, EP, and USP norms, ensuring regulatory acceptance in Europe, North America, and other demanding markets.
Regulatory agencies and customs authorities track bulk and packaged maltose using the numeric HS Code 1702.50, which serves as the identifier for maltose including pure and blended forms. Use of this international classification simplifies import, export, and tax documentation and helps ensure compliance in cross-border transactions. Official specification sheets highlight blueprint features such as assay (not less than 98% on anhydrous basis), moisture content (typically below 6%), optical rotation parameters, chloride and sulfate absence, and specified absence of insoluble particles. Each batch must clear microbial load testing, including total aerobic microbial count, yeast, and mold count, further minimizing risks to patients or consumers.
Within pharmaceutical manufacturing, maltose BP EP USP Pharma Grade plays a key role as a stabilizer, a bulking agent, or as a fermentable sugar that supports the growth of probiotic bacteria in syrup bases. Its precise physical and chemical attributes allow tablets to form with reliability and solutions to maintain their intended performance in diagnostic kits. Maltose’s gentle sweetness supports taste-masking functions without adding reactive or allergenic substances to sensitive formulations. In addition to medicinal uses, specific forms integrate with nutritional products and certain specialized food lines under expert oversight to maintain clean labeling and known allergen profiles.
Relying on high-specification maltose under these pharmacopoeial frameworks means product developers, quality assurance professionals, and regulatory teams can work with confidence that every batch performs as expected. Past experiences in R&D environments underscore how trace contaminants or inconsistent crystalline properties can derail batch integrity or clinical trials involving oral solutions. Addressing such risks calls for close ties between raw material suppliers, certification bodies, and company-level quality assurance, focusing not only on product assay but also on trace-level impurity profiles, moisture, and environmental durability. Steps forward point toward innovation in packaging, improvements in real-time batch tracking, and next-generation contamination control that combine the foundation provided by existing BP, EP, and USP guidelines with industry-led advances in risk management, analytical precision, and sustainable supply chain stewardship.
Chengguan District, Lanzhou, Gansu, China
